Longeveron receives Japanese patent for potency assay methods to assess human mesenchymal stem cells
Longeveron receives Japanese patent for potency assay methods to assess human mesenchymal stem cells: Miami Saturday, January 31, 2026, 13:00 Hrs [IST] Longeveron Inc, a clinical ...
NIHR announces a £15 million investment over 5 years in its NIHR PHIRST: United Kingdom Saturday, January 31, 2026, 12:00 Hrs [IST] The NIHR has announced a £15 million investme ...
Wadi Surgicals highlights pain points, expectations of the glove manufacturing sector ahead of Union Budget 2026: Shardul Nautiyal, Mumbai Saturday, January 31, 2026, 11:50 Hrs [I ...
Almirall’s Seysara receives China NMPA approval for treatment of moderate-to-severe acne: Barcelona, Spain Saturday, January 31, 2026, 11:00 Hrs [IST] Almirall, S.A, a global ph ...
AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals: Cambridge, UK Saturday, January 31, 2026, 09:00 Hrs [IST] AstraZene ...
Shardul Nautiyal, Mumbai Saturday, January 31, 2026, 08:00 Hrs [IST] ...
The Union health ministry has issued a draft notification with a proposal to correct the strength of folic acid with regard to its unit of measurement from milligram (mg) to micrograms (mcg), under ...
Indian healthcare industry sees facility management as critical component for better patient recovery: Nandita Vijayasimha, Bengaluru Saturday, January 31, 2026, 08:00 Hrs [IST] I ...
The Union ministry of health and family welfare has issued a draft notification to amend the Drugs Rules, 1945 to include analgesic drug Pregabalin and its drug formulations under the Schedule H1 of ...
JPSC to recruit 30 drug inspectors, applications open until February 18: Our Bureau, Chennai Saturday, January 31, 2026, 08:00 Hrs [IST] The Jharkhand Public Service Commission (J ...
Pondicherry drugs control department issues recall for three ‘Not of Standard Quality’ products: Peethaambaran Kunnathoor, Chennai Saturday, January 31, 2026, 08:00 Hrs [IST] ...
Ascletis reports positive results from phase III open-label study of denifanstat, a first-in-class, once-daily oral FASN inhibitor for acne: Hong Kong Friday, January 30, 2026, 16 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results